FXN Frataxin Restoration Program
Edit / manage →Friedreich ataxia
Overview
- Disease area
- Neurodegeneration
- Indication
- Friedreich ataxiaMONDO:0100339
- Mechanism of action
- Frataxin expression restoration in dorsal root ganglia
- Development stage
- IND-enabling
- Institution
- Greenfield Institute for Rare Disease
- Principal investigators
- A. Petrov
- Targets
- FXN
- Pathways
- Mitochondrial function
- Trial registry
- —
Scientific assessment
1 claims- Target ValidationStrong
Frataxin deficiency drives mitochondrial iron-sulfur cluster failure in Friedreich ataxia; restoring expression is mechanistically grounded.
Translational assessment
1 claims- EndpointsLimited
mFARS is the accepted clinical endpoint; DRG-targeted dosing must balance frataxin restoration against overexpression toxicity.
internalendpoint-2024
Regulatory assessment
0 claimsNo evidence linked yet.
Commercial assessment
0 claimsNo evidence linked yet.
Execution assessment
0 claimsNo evidence linked yet.
Structured reviews
1 reviewsStrong mechanistic grounding in frataxin biology.
Overexpression toxicity window; DRG-targeted delivery unproven.
Establish therapeutic index in vivo before IND-enabling.
Internal rubric input (reviewer scoring — not a success probability)
Outcome
- ActiveIND-enabling; therapeutic-index work ongoing.2025-01-10
AI brief
flag off · defaultPhase 7Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.
Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.